Introduction {#s1}
============

Repair of lost axonal connections generally fails to occur after neuronal injury in the adult mammalian central nervous system (CNS). This failure is not only a reflection of the growth inhibitory nature of CNS tissue ([@bib13]; [@bib14]; [@bib48]), but also due to the lack of intrinsic capacity for neurons in the adult CNS to grow axons ([@bib29]; [@bib50]). However, landmark studies by Richardson and Issa have suggested that neurons indeed possess an innate ability to regenerate their axons in the adult mammalian CNS, and that this ability can be unlocked by a 'conditioning lesion' ([@bib44]). In adult DRG neurons, an injury to peripherally projecting axons, i.e. a compression injury to the sciatic nerve, unleashes growth programs within the DRG and allows for regeneration of its centrally projecting axons in the spinal cord ([@bib37]; [@bib44]). This growth can be induced by a lesion in the peripheral nervous system (PNS) even after the CNS lesion has occurred ([@bib68]), hence it is of great interest from a therapeutic perspective to understand the molecular mechanisms that allow for the unlocking of such regenerative potential.

Previous studies have discovered that several signal transduction pathways are activated in DRG neurons upon a conditioning injury, including JAK-STAT3 ([@bib42]), ATF3 ([@bib12]; [@bib23]), Smad1 ([@bib69]), Activin ([@bib39]), HIF-1alpha ([@bib6]) and cAMP ([@bib43]; [@bib36]; [@bib5]). Impressively, ectopic elevation of cAMP alone is sufficient to strongly enhance regeneration ([@bib60]; [@bib43]; [@bib36]). Since this second messenger is commonly modulated by growth signals and neuronal activity, cAMP modulation has been suggested as a potential therapeutic inroad to stimulate the regenerative potential of neurons ([@bib60]). However, the downstream pathways that are engaged by this broadly utilized second messenger to actually promote axonal regeneration are not known. Much attention has focused upon the cAMP-responsive element binding protein (CREB), since constitutive activation of CREB is sufficient to stimulate axonal regeneration in the presence of CNS myelin *in vivo* ([@bib17]). However, more recent studies indicate that endogenous CREB is not required for cAMP elicited axonal regeneration *in vitro* ([@bib30]). Hence it remains elusive how cAMP elevation activates axonal regrowth programs in neurons.

A recent study has identified an essential role for the dual zipper-bearing kinase DLK in the pro-regenerative effect of a conditioning lesion in adult DRG neurons ([@bib46]). Similarly, the *Drosophila* homologue Wallenda (Wnd), mediates protective effects of a conditioning lesion in *Drosophila* motoneurons ([@bib3]; [@bib61]). This conserved axonal mitogen activated kinase kinase kinase (MAPKKK) is thought to function as a sensor of axonal damage, and therefore should become activated upon conditioning injury. In support of this, Wnd/DLK is transported in axons ([@bib63]) and is required acutely in injured axons for the generation of signals that are retrogradely transported to the cell body ([@bib63]; [@bib46]). DLK/Wnd is required for axonal regeneration in many types of neurons, including motoneurons in mammals, flies and worms, and CNS neurons where regeneration is ectopically induced by PTEN mutations ([@bib67]; [@bib20]; [@bib63]; [@bib46]; [@bib56]). Conversely, in mammalian CNS neurons that do not regenerate (eg. retinal ganglion cells, RGCs), DLK activation after injury mediates cell death ([@bib57]; [@bib56]).

Collectively, these findings support the model that a conserved function of the Wnd/DLK kinase is to 'sense' axonal damage. Through a yet unknown mechanism, axonal damage leads to activation of Wnd/DLK's kinase function. Once activated, downstream signaling mediates both beneficial and deleterious outcomes in neurons, depending upon the context. The high stakes outcomes of regeneration or death, combined with additional findings that DLK mediates cell death in models for nerve growth factor withdrawal ([@bib24]; [@bib18]), glaucoma ([@bib57]), MPTP toxicity ([@bib32]) and excitotoxicity ([@bib41]), have inspired much interest in understanding the unknown pathways that lead to the activation of DLK/Wnd in injured axons.

Here we identify a direct upstream activator of DLK/Wnd in injured axons, in the form of the cAMP effector kinase PKA. We find that PKA phosphorylates evolutionarily conserved serines within the activation loop of DLK, which is sufficient to activate DLK independently of its downstream signaling mechanisms. In addition, our functional studies in both *Drosophila* motoneurons and adult mammalian DRG neurons indicate that the ability of cAMP and PKA to promote axonal regeneration depends entirely upon the ability of PKA to activate the DLK/Wnd kinase. These findings present a unified and evolutionarily conserved molecular pathway, from cAMP to PKA to DLK, which plays a central role in stimulating the ability of injured axons to regenerate.

Results {#s2}
=======

PKA regulates axonal regeneration via Wnd {#s2-1}
-----------------------------------------

Previous studies in mammalian and *C. elegans* neurons suggest that cAMP signaling stimulates regenerative axonal growth ([@bib43]; [@bib36]; [@bib5]; [@bib19]). To study this axon regeneration pathway in *Drosophila*, we used previously developed axon injury assay in third instar larvae ([@bib63]), and found that knockdown of phosphodiesterase *dunce (dnc*) or activation of PKA by overexpression of the catalytic subunit (PKA^CA^) ([@bib28]) led to an enhanced growth response of *Drosophila* motoneuron axons after nerve crush injury ([Figure 1A](#fig1){ref-type="fig"}). The new axonal growth from the injured proximal stump generally assumes a highly branched shape, characterized by a network of small branches and a general thickening of the axon diameter. To assess the injury response, we quantified the total membrane volume within 100 µm of the axonal tip (indicated by the dash line in [Figure 1A](#fig1){ref-type="fig"}). In control animals, this total volume increases 3 fold, from 68.5 µm^3^ to 200 µm^3^ 15 hr after injury. PKA activation led to a 1.5 fold increase in this volume compared to control (WT) axons ([Figure 1B](#fig1){ref-type="fig"}). The enhanced sprouting response stimulated by PKA was lost when DLK/Wnd function was inhibited by co-expression of RNAi targeting Wnd (but not a control RNAi) ([Figure 1A and B](#fig1){ref-type="fig"}). These observations are consistent with the previous finding in *C.elegans* that DLK is required for the regeneration that is induced by cAMP signaling ([@bib19]). In addition, PKA alone is required for *Drosophila* motoneurons to initiate regenerative sprouting, as RNAi-mediated knockdown of the PKA catalytic subunit inhibited the sprouting response by 50% compared to control axons ([Figure 1A and B](#fig1){ref-type="fig"}). cAMP and PKA therefore play an influential role in the regenerative capacity of *Drosophila* motoneuron axons.10.7554/eLife.14048.003Figure 1.PKA stimulates and is required for axonal regeneration in *Drosophila* motoneurons.Single motoneuron axons were labeled by expression of UAS-mCD8-GFP using the m12-Gal4 driver and imaged either 0 hr or 15 hr after nerve crush injury. Representative images are shown in (**A**), while (**B**) shows quantification of the increased volume in axonal membrane, which is measured within 100 µm of the proximal axon tip, indicated in dotted line. Genotypes used in (**A**): wild type (WT) (;;m12-Gal4, UAS-mCD8GFP/+); *control*-RNAi (UAS-*dcr2*;; UAS-*moody*-RNAi/m12-Gal4, UAS-mCD8GFP); *dnc-*RNAi (UAS-*dcr2*;; UAS-*dnc*-RNAi/m12-Gal4,UAS-mCD8GFP); *wnd*-RNAi (UAS-*dcr2*;; UAS-*wnd*-RNAi/m12-Gal4,UAS-mCD8GFP); PKA^CA^(; UAS-PKA^CA^/+; UAS-mCD8GFP/+); PKA^CA^,*control*-RNAi (UAS-*dcr2*; UAS-PKA^CA^/+; UAS-*moody*-RNAi (VDRC 100674)/m12-Gal4, UAS-mCD8GFP); PKA^CA^,*wnd*-RNAi (UAS-*dcr2*; UAS-PKA^CA^/+; UAS-*wnd*-RNAi/m12-Gal4, UAS-mCD8GFP); *pka-c1*-RNAi (UAS-*dcr2*; UAS-*pka-c1*-RNAi/+; m12-Gal4, UAS-mCD8GFP \[using two different lines, Bloomington 31277 and 35169\]). All data are represented as mean ± SEM; At least 10 animals (≥50 axons) are examined per genotype; \*\*\*p\<0.001; 'n.s.' indicates non-significant; scale bar, 100 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14048.003](10.7554/eLife.14048.003)

PKA modulates the levels of Wnd and downstream signaling in *Drosophila* neurons {#s2-2}
--------------------------------------------------------------------------------

While the above and previously described genetic interactions ([@bib19]) suggest a relationship, whether Wnd/DLK functions downstream of PKA or in a parallel pathway cannot be discerned from genetic epistasis alone. To probe the relationship between PKA and Wnd, we first utilized previously established tools in *Drosophila* for monitoring the activation of Wnd and downstream nuclear signaling. Wnd signaling induces expression of the c-Jun N-terminal Kinase (JNK) phosphatase puckered (*puc*), which can be measured as lacZ expression using fly lines that contain the *puc*-lacZ enhancer trap reporter ([@bib63]). *Puc-*lacZ is expressed at low levels in uninjured motoneurons, however it is induced by axonal injury in a manner that requires both Wnd and JNK kinase function ([@bib63]). We found expression of either *dnc*-RNAi or PKA^CA^ induced the expression of *puc*-lacZ in motoneurons ([Figure 2A](#fig2){ref-type="fig"}). This induction is Wnd dependent, as RNAi knockdown of Wnd (but not a control RNAi) rescued the *puc-*lacZ elevation ([Figure 2A](#fig2){ref-type="fig"}).10.7554/eLife.14048.004Figure 2.PKA modulates the levels of Wnd protein and downstream signaling in *Drosophila* neurons.(**A**) The *puc*-lacZ transcriptional reporter for Wnd/JNK signaling indicates that activated PKA stimulates Wnd signaling. A pan-neuronal driver (BG380-Gal4) is used to express UAS-*dnc-*RNAi, UAS-PKA^CA^ or UAS-PKA^CA^ together with UAS-*wnd*-RNAi or a *control*-RNAi. Example images are shown of cell bodies in the dorsal midline of the ventral nerve cord; (all but two of these neurons are motoneurons). Quantification (described in methods) was carried out for 10 animals per genotype. (**B**) Endogenous Wnd protein levels are increased in PKA^CA^ expressing neurons. Ventral nerve cords were dissected from third instar larvae (BG380-Gal4 \[WT control\] and BG380-Gal4; UAS-PKA^CA^/+) and processed for Western blotting with anti-Wnd and anti-tubulin antibodies. The quantification shows Wnd/tubulin ratios (normalized to WT control) averaged from 3 independent experiments (25 nerve cords per experiment). (**C**) PKA increases DLK levels via a posttranscriptional mechanism. GFP-tagged kinase dead Wnd (GFP-Wnd^KD^) was ectopically expressed using m12-Gal4 driver (WT control) or co-expressed with UAS-PKA^CA^ and imaged directly after fixation. Example images and quantification of GFP-Wnd^KD^ intensity in cell bodies and axons within segmental nerves. n\>10 animals for each condition. (**D**) PKA-C1 is required for induction of Wnd protein after axonal injury. Example images and quantification of GFP-Wnd^KD^ in nerve cords and segmental nerves before and after (8 hr) injury. UAS-GFP-Wnd^KD^ was expressed in motoneurons by OK6-Gal4. WT or together with UAS-*pka-c1*-RNAi or UAS-*moody*-RNAi (control) and imaged similarly to [Figure 2C](#fig2){ref-type="fig"}. The quantification method for GFP intensity is described in materials and methods. n\>10 animals for each condition. All data are represented as mean ± SEM; \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05, 'n.s.' indicates non-significant; scale bars, 10 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14048.004](10.7554/eLife.14048.004)

Previous studies in multiple organisms suggest that Wnd/DLK is highly regulated at the level of protein turnover and increased levels of DLK correlate with the activation of downstream signaling ([@bib63]; [@bib24]; [@bib57]; [@bib9]; [@bib35]; [@bib38]; [@bib20]). We therefore tested whether PKA activation altered Wnd levels. The total levels of endogenous Wnd within 2nd instar larval brains were significantly elevated (by 75%) when PKA^CA^ was expressed in neurons ([Figure 2B](#fig2){ref-type="fig"}).

To test whether the change of Wnd level is due to a posttranscriptional mechanism, we used the Gal4/UAS system to ectopically express a GFP tagged Wnd transgene in *Drosophila* motoneurons. Since overexpression of WT Wnd can cause lethality, we expressed an inactive (kinase dead) version (GFP-Wnd^KD^) that contains a point mutation in the kinase domain ([@bib9]). We found that expression of PKA^CA^ induced a 12-fold increase in the levels of GFP-Wnd^KD^ in motoneuron axons ([Figure 2C](#fig2){ref-type="fig"}). In contrast, GFP-Wnd^KD^ was not significantly altered in cell bodies ([Figure 2C](#fig2){ref-type="fig"}).

The increase in axonal GFP-Wnd^KD^ when PKA is induced has remarkable similarity to what occurs in axons after injury ([@bib63]; [@bib24]). We therefore tested whether PKA is required for the induction of Wnd in proximal axons after nerve crush injury. In control (WT) motoneurons, a significant increase in the mean intensity of the GFP-Wnd^KD^ was observed 7 hr after injury ([Figure 2D](#fig2){ref-type="fig"}). This increase is abolished by co-expression of RNAi targeting PKA-C1, but not a control RNAi ([Figure 2D](#fig2){ref-type="fig"}). These observations suggest that PKA is required for the activation of Wnd signaling and the induction of Wnd protein levels downstream of axonal injury.

PKA activates DLK through phosphorylation of its activation loop {#s2-3}
----------------------------------------------------------------

To test whether the regulation of DLK by PKA is conserved in mammalian neurons, we examined endogenous DLK protein in cultured embryonic rat cortical neurons. Treatment with forskolin, which activates PKA via elevation of cAMP, led to a 2-fold increase in the level of endogenous DLK protein ([Figure 3A](#fig3){ref-type="fig"}). This effect of cAMP elevation requires PKA, since the increase in DLK levels was abolished by co-treatment with the PKA inhibitor H-89 ([Figure 3A](#fig3){ref-type="fig"}). In contrast, treatment with H-89 alone led to a significant reduction in the DLK levels ([Figure 3B](#fig3){ref-type="fig"}). Similar results were observed in HEK293 cells co-transfected with Flag-tagged DLK and either a control empty plasmid or PKA^CA^. PKA^CA^ induces an approximately two-fold increase in DLK protein levels ([Figure 3E](#fig3){ref-type="fig"} and [4B](#fig4){ref-type="fig"}). PKA^CA^ also stimulates a phosphatase-sensitive increase in DLK molecular weight, which is most visible when equal amounts of DLK protein are compared ([Figure 3F](#fig3){ref-type="fig"}).10.7554/eLife.14048.005Figure 3.PKA activates DLK via phosphorylation of its activation loop.(**A-B**) Changes in endogenous DLK abundance in response to treatment with forskolin (30 µM) (**A**) or the PKA inhibitor H-89 (5 µM) (**B**) for 6 hr in cultured rat embryonic cortical neurons. Quantification shows relative DLK/Tubulin levels in western blots. (**C**) Alignment of activation loop sequences in different species. (**D**) The anti-pDLK^S302^ antibodies recognize transfected Flag-DLK^WT^, but not activation loop mutation Flag-DLK^S301A,S305A^. Both proteins were transiently expressed in HEK293 cells. Western blots were probed with anti-pDLK^S302^ antibody, anti-Flag antibody to detect the total DLK expression levels, and anti-Tubulin (which remains similar in all manipulations) for normalization. (**E**) PKA^CA^ stimulates phosphorylation of DLK S302 in HEK293 cells. HEK293 cells were co-transfected with Flag-tagged DLK^WT^ and an empty control plasmid or PKA^CA^. Cell lysates were probed with anti-DLK antibody, anti-pDLK^S302^ antibody, anti-PKA C antibody and anti-tubulin antibody. (**F**) PKA^CA^ stimulates an increase in DLK molecular weight. Flag-DLK protein was immunoprecipitated from HEK293 cells co-transfected with DLK and either Flag-tagged DLK^WT^ and an empty control plasmid or PKA^CA^. The immunoprecipitated Flag-DLK was then incubated with either glycerol (control) or lambda protein phosphatase (λPP). PKA^CA^ induced a upward shift in DLK molecular weight, which was lost upon phosphatase treatment. (**G**) The activation loop is required for axonal regeneration in *Drosophila* neurons. Single axons in *Drosophila* third instar larva are labeled by mCD8RFP using eve-Gal4 driver. 24 hr after injury, these neurons in animals heterozygyous for *wnd (wnd*^3^/+) show robust axonal sprouting. However, sprouting fails to occur in *wnd*^3^/*wnd*^3^ animals. Expression of UAS-Wnd (WT) can restore axonal regeneration in *wnd* mutant background (UAS-Wnd, *wnd*^3^; *wnd*^3^,eve-Gal4, UAS-mCD8RFP). However, expression of activation loop mutant UAS-Wnd^S301A,S305A^ failed to rescue the sprouting defect in *wnd* mutant animals (UAS-Wnd^S301A,S305A^, *wnd*^3^; *wnd*^3^, eve-Gal4,m12-mCD8RFP). Quantification of the volume of axonal membrane within 100 µm of the distal ending of the proximal stump. n\> 50 axons for each genotype. Data are presented as mean ± SEM for 3 independent experiments; \*\*\*p\<0.001; scale bar, 100 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.14048.005](10.7554/eLife.14048.005)10.7554/eLife.14048.006Figure 3---figure supplement 1.PKA can directly phosphorylate DLK at S302.(**A**) PKA can induce DLK S302 phosphorylation *in vitro*. Flag-DLK was purified from HEK293 cells by anti-Flag immunoprecipitation and used for an *in vitro* kinase activity with purified PKA catalytic subunit. 5 µg of purified DLK was incubated with or without 10,000 U PKA catalytic subunit. Equal amounts of DLK in both samples (as demonstrated by probing with anti-DLK antibody) were analyzed by western blotting with anti-pDLK^S302^ antibody. (**B**) Quantification shows relative pDLK^S302^/total DLK levels.**DOI:** [http://dx.doi.org/10.7554/eLife.14048.006](10.7554/eLife.14048.006)10.7554/eLife.14048.007Figure 3---figure supplement 2.DLK activation by PKA does not require TORC1.(**A-B**) The phosphorylation level of DLK S302 is not sensitive to treatments of TORC1 inhibitors. HEK293 cells were either untransfected or transfected with Flag-DLK^WT^ + empty plasmid or Flag-DLK^WT^ + PKA^CA^. Cells were treated with torin1 (**A**) or rapamycin (**B**) for 2 hr. The efficiency of the drugs were demonstrated by probing with anti-phospho-S6K antibody.**DOI:** [http://dx.doi.org/10.7554/eLife.14048.007](10.7554/eLife.14048.007)10.7554/eLife.14048.008Figure 4.PKA promotes the stability of DLK independently of DLK downstream signaling.(**A-B**) Activation of PKA promotes DLK stability independently of JNK. HEK293 cells were transiently transfected with Flag-DLK^WT^, and (**A**) treated with forskolin (6 hr, 30 µM) or (**B**) co-transfected with either PKA^CA^ or empty vector (control). In both cases, co-treatment with JNK inhibitor VIII (10 µM, 6 hr) led to a decrease in total Flag-DLK levels. However, both forskolin and PKA^CA^ induced an increase in DLK levels even in the presence of JNK inhibitor. Quantification shows average total DLK/Tubulin intensities and average pDLK^S302^/total DLK ratios (where total DLK is detected using anti-Flag antibody). All data are represented as mean ± SEM; quantifications of relative intensity from Western Blots were averaged from 3 independent experiments; \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05, 'n.s.' indicates non-significant. (**C-D**) Activation of PKA increases the stability of kinase dead DLK mutants, DLK^K185A^ (**C**) and DLK^S302A^ (**D**). HEK293 cells were transiently transfected with Flag-DLK^K185A^ or Flag-DLK^S302A^ together with PKA^CA^ or empty plasmid. Treatment JNK inhibitor VIII (10 µM) for 6 hr had no effect upon the PKA^CA^ induced levels of DLK^K185A^ and DLK^S302A^ mutant protein. Quantifications are similar to [Figure 4A--B](#fig4){ref-type="fig"}. Western bands intensity were averaged from 4 independent experiments; data are shown as mean ± SEM; \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05, 'n.s.' indicates non-significant. (**E**) Proposed model for the activation and stabilization of DLK by cAMP and PKA. cAMP elevation and PKA activation leads to the phosphorylation of S302 on DLK, which activates its kinase activity. Indicated in the blue arrow, downstream signaling via JNK leads to enhanced DLK stability and phosphorylation of DLK at other sites ([@bib24]). PKA also enhances DLK's stability via an additional mechanism that is independent of S302 (red arrow).**DOI:** [http://dx.doi.org/10.7554/eLife.14048.008](10.7554/eLife.14048.008)10.7554/eLife.14048.009Figure 4---figure supplement 1.Summary of predicted PKA phosphorylation sites on DLK/Wnd in different species.The sequence of DLK homologues in different species (human, mouse, *Drosophila* and *C. elegans*) were analyzed by Group-based Prediction System (GPS) to computationally predict PKA phosphorylation sites ([@bib65]; [@bib64]). Identified potential PKA^CA^ phosphorylation motifs in different species are shown, with the phosphorylation site highlighted in red. Numbering is shown for mouse DLK. Two sites, S302 and S389, are conserved among all the species. Other sites are conserved in mammals, while fly DLK has a similar number of sites but in distinct locations. Not shown, *C. elegans* DLK also has 11 additional predicted sites, but at distinct locations from mammalian and fly DLK.**DOI:** [http://dx.doi.org/10.7554/eLife.14048.009](10.7554/eLife.14048.009)

Although the mechanism of DLK activation is unknown, phosphorylation of the activation loop is important for activation of other kinases in the mixed lineage kinase family that DLK belongs to ([@bib11]; [@bib25]). Notably, the activation loop contains a conserved consensus sequence for PKA ([Figure 3C](#fig3){ref-type="fig"}), and a recent study has demonstrated that the predicted phosphorylation site S302 is required for DLK to activate downstream kinases ([@bib24]).

To test whether PKA stimulates phosphorylation of DLK's activation loop (S302), we have generated phospho-specific antibodies against a phosphorylated peptide corresponding to activation loop of mouse DLK (KELSDKpSTKMpSFAGTV). The phospho-DLK antibodies detected a strong band in HEK293 cells that overexpress WT mouse DLK, but show no reactivity for mutant DLK^S302A^ ([Figure 3D](#fig3){ref-type="fig"}). Remarkably, expression of PKA^CA^ in HEK293 cells induces a dramatic increase of phospho-S302 DLK ([Figure 3E](#fig3){ref-type="fig"}), even when normalized to the levels of total DLK ([Figure 4B](#fig4){ref-type="fig"}). Similar results were observed when cells were treated with forskolin for 3 hr ([Figure 4A](#fig4){ref-type="fig"}).

Since the activation loop contains a conserved consensus sequence for PKA substrates, it should be capable of phosphorylating this site in DLK directly. Indeed, we found that purified PKA can strongly stimulate pS302 reactivity upon purified Flag-DLK *in vitro* ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

A recent study in *Drosophila* has suggested that TORC1 may activate and phosphorylate Wnd ([@bib58]), so we considered whether TORC1 plays a role in the activation of DLK by PKA. We used both torin1 and rapamycin to inhibit TORC1 in the presence or absence of PKA in HEK293 cells. However, in both cases we observed no effect upon DLK and pDLK levels ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). PKA therefore stimulates phosphorylation of DLK's activation loop independently of TORC1 function.

To confirm that S302 is a critical site for Wnd/DLK function in axonal regeneration, we conducted a rescue experiment in *Drosophila* motoneurons based on the requirement of Wnd for axonal sprouting after injury. We generated UAS-Wnd^S301A,S305A^ transgenic flies expressing Wnd with mutations in two serines analogous to S298 and S302 in the activation loop of DLK. As shown in [Figure 3G](#fig3){ref-type="fig"}, all axons in *wnd* mutants fail to initiate a sprouting response, which can be rescued by co-expression of WT Wnd, but not Wnd^S301A,S305A^. In addition, overexpression of Wnd^S301A,S305A^ does not give rise to any of the previous described gain-of-function phenotypes similar to WT Wnd, suggesting that S302 is indeed required for DLK function.

PKA promotes DLK stability independently of downstream signaling {#s2-4}
----------------------------------------------------------------

A previous study has described a positive feedback loop for DLK stabilization that involves the action of DLK's downstream effector JNK ([@bib24]). JNK activation stimulates phosphorylation of DLK at sites outside of its activation loop (T43 and S533) and changes DLK's sensitivity to degradation via the ubiquitin proteasome system (UPS) ([@bib24]). This increase in protein stability leads to an increase in total levels of DLK. Since PKA stimulates an increase in ectopically expressed DLK, it most likely increases protein stability. We therefore tested whether this increased stability involves the previously described JNK-dependent feedback mechanism. If this is the case, the effects of PKA and forskolin should depend on the function of JNK. As shown in [Figure 4A and B](#fig4){ref-type="fig"}, treatment with JNK inhibitor VIII led to a 30% decrease in total DLK level, as expected for JNK's previously demonstrated role in promoting DLK stability. However, even in the presence of JNK inhibitor, treatment with forskolin ([Figure 4A](#fig4){ref-type="fig"}) or transfection with PKA^CA^ ([Figure 4B](#fig4){ref-type="fig"}) increases DLK level by 50%. Moreover, treatment with JNK inhibitor had very little effect upon the fraction of total DLK that is phosphorylated at S302 ([Figure 4A and B](#fig4){ref-type="fig"}). These results suggest that PKA stimulates DLK phosphorylation and stabilization independently of downstream JNK activation.

Previous biochemical studies suggest that DLK's activation mechanism is associated with dimerization and autophosphorylation ([@bib38]; [@bib31]; [@bib34]). We therefore further considered whether PKA could function either upstream or downstream of DLK's own ability to function as a kinase. To test this, we utilized a kinase-dead version of DLK, DLK^K185A^, which is unable to activate downstream signaling or undergo autophosphorylation ([@bib38]; [@bib31]; [@bib34]). Consistent with the previously described feedback mechanism ([@bib24]), the DLK^K185A^ mutant protein was less stable, and addition of JNK inhibitor had no further effect upon the levels of kinase dead DLK protein ([Figure 4C](#fig4){ref-type="fig"}). However, PKA^CA^ stimulated a strong increase of DLK^K185A^ levels and phosphorylation at S302 for DLK^K185A^. The ability of PKA to increase DLK protein stability and activation loop phosphorylation independently of DLK's own signaling abilities places PKA firmly upstream of DLK, as an upstream regulator/activator.

Since PKA promotes DLK stability and directly phosphorylates S302, we wondered whether PKA stabilizes DLK by phosphorylation of S302. Previous work has shown that a decreased stability for DLK^S302A^ mutant protein is linked to the fact that it is inactive for kinase activity, and is therefore unable to activate the downstream stabilization mechanism via JNK ([@bib24] and [Figure 4D](#fig4){ref-type="fig"}). Consistent with this, the reduced levels of DLK^S302A^ protein are not further reduced in the presence of JNK inhibitors ([Figure 4D](#fig4){ref-type="fig"}). However surprisingly, co-transfection with PKA^CA^ still caused an increase of the levels of DLK^S302A^ protein ([Figure 4D](#fig4){ref-type="fig"}). We interpret that PKA regulates DLK via an additional mechanism, in conjunction with phosphorylation of the critical activation loop S302. This additional mechanism may involve other sites of phosphorylation, or other modes of regulation (discussed further below).

PKA stimulates axonal regeneration via DLK in adult DRG neurons {#s2-5}
---------------------------------------------------------------

Our finding that PKA activates DLK, taken together with previous findings that DLK promotes axonal regeneration in different neuronal cell types ([@bib46]; [@bib63]; [@bib20]; [@bib67]), led to the hypothesis that DLK is an important downstream mediator of cAMP-stimulated axon regeneration. To test this hypothesis, we employed a recently described replating assay for DRG neurons cultured from adult mice, which allows for a controlled and quantitative measure of the induction of axonal regeneration by *in vitro* manipulations such as forskolin treatment ([@bib15]; [@bib53]). In this assay (depicted in [Figure 5A](#fig5){ref-type="fig"}), DRG neurons removed from adult mice were first cultured for 4--5 days, which allowed for the regenerative response activated by the dissection to subside. Neurons were then treated with forskolin for 24 hr, and then replated onto a fresh dish. The replating process removes all existing neurites so that the neurites observed within the second culture period can be identified as new growth. As shown in [Figure 5B and E](#fig5){ref-type="fig"}, treatment with forskolin stimulates the regenerative response ([@bib15]). In addition, co-treatment with H-89 abolished the effect of forskolin on neurite outgrowth ([Figure 5B--D](#fig5){ref-type="fig"}), suggesting that PKA is required.10.7554/eLife.14048.010Figure 5.PKA stimulates axonal regeneration via DLK in adult DRG neurons.(**A-D**) Induction of regeneration by forskolin requires PKA. Experimental design (A and also see Materials and Methods). To demonstrate that forskolin-induced neurite outgrowth is mediated by PKA, we assessed whether PKA signaling was required using the PKA inhibitor H-89 (PKAi, 5 µM). Representative neurons are shown in (**B**). Neurite outgrowth was assessed by quantifying mean neurite length (**C**) and distribution of longest neurite (**D**). Data are mean ± SEM for 4 independent experiments. (**E-G**) Induction of regeneration by forskolin requires DLK. WT and DLK KO neurons were treated with DMSO or forskolin (30 µM) as described in (**A**). Representative neurons are shown in (**E**). Neurite outgrowth was assessed by quantifying mean neurite length (**F**) and distribution of the longest neurite (**G**). Data are mean ± SEM for 3 independent experiments. \*\*\*p\<0.001, \*\*p\<0.01, \*p\<0.05, 'n.s.' indicates non-significant; scale bars, 100 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.14048.010](10.7554/eLife.14048.010)10.7554/eLife.14048.011Figure 5---source data 1.Measurements of the longest neurite length for 100 neurons after replating in each condition.The longest neurite length for 100 WT neurons after replating in four different conditions (DMSO+Vehicle, DMSO+forskolin, PKA inhibitor+Vehicle, PKA inhibitor+forskolin) are shown in Table 'PKAi'. This table contains data from 4 independent experiments. The longest neurite length for 100 DLK KO neurons after replating in two different conditions (DMSO and forskolin) are shown in Table 'DLK KO'. The table contains data from 3 independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.14048.011](10.7554/eLife.14048.011)

To determine whether forskolin-induced neurite outgrowth requires DLK, we performed the same experiment in neurons from DLK (Map3k12) conditional knockout (KO) mice and littermate controls. The effects of forskolin on neurite outgrowth were abolished in DLK conditional knockout DRG neurons ([Figure 5E--G](#fig5){ref-type="fig"}). These findings suggest that DLK and its downstream signaling pathway(s) are important mediators of the pro-regenerative effects of cAMP elevation in neurons.

Discussion {#s3}
==========

The Wnd/DLK kinase is likely to function as a sensor of axonal damage. Depending upon the context, its activation can lead to either axonal regeneration or cell death and degeneration ([@bib52]). The factors that determine beneficial versus detrimental outcomes, along with the general cellular mechanisms that lead to the activation of DLK, are poorly understood. In this study, we found that an immediate upstream activator of DLK is the cAMP regulated kinase PKA. Elevation of cAMP signaling, which is activated by pro-regenerative manipulations such as a conditioning lesion, is the most widely known pathway for promoting axonal regeneration ([@bib21]). We found that an essential component of this regenerative pathway is the activation of Wnd/DLK by PKA. These findings delineate an evolutionarily conserved mechanism for the activation of the Wnd/DLK kinase. Taken together with previous findings that Wnd/DLK is an essential regulator of responses induced by a conditioning injury ([@bib46]; [@bib61]), the activation of Wnd/DLK by PKA in injured axons presents a unified molecular pathway for activating a regenerative response to axonal damage.

In contrast to a merging of cAMP and DLK pathways, some other studies have suggested that these pathways may act separately ([@bib27]; [@bib8]). A recent study has noted that in certain sensory neuron types in *C. elegans*, PKA *gain-of-function* mutations can induce axonal outgrowth even in *dlk* mutants ([@bib8]). Hence, multiple pathways for axonal regeneration may be inducible by PKA. However DLK is strongly required for cAMP stimulated regeneration in other neuron types in *C. elegans* ([@bib19]), and, importantly, in axonal regeneration induced by a conditioning lesion in the mammalian PNS ([@bib46]). Our findings now indicate that DLK is an important molecular target and effector of cAMP-induced regeneration in mammalian neurons.

Previous biochemical studies indicate that DLK activation involves dimerization via its leucine zipper domains and autophosphorylation, at locations that are yet undefined ([@bib38]; [@bib31]). Because ectopic elevation of DLK/Wnd protein is sufficient to activate its downstream signaling ([@bib31]; [@bib38]; [@bib24]), and DLK is known to be highly regulated at the level of protein turnover ([@bib9]; [@bib63]; [@bib24]; [@bib35]; [@bib20]), a plausible mechanism for its regulation is to hold its levels and/or its ability to dimerize in check ([@bib31]; [@bib38]). The existence of a direct upstream activator of the kinase was not previously implied, and has thus far been unknown. Here we found that PKA stimulates the phosphorylation of the activation loop of DLK independently of DLK's kinase activity, and also independently of downstream JNK signaling. This defines PKA as an upstream activator of DLK.

A previous study in *C. elegans* has described a mechanism through which transient elevation of intracellular Ca^2+^ upon axonal injury leads to the activation of DLK-1 ([@bib66]; [@bib7]; [@bib19]; [@bib49]). In addition, earlier studies have implicated calmodulin-regulated calcineurin in the regulation of mammalian DLK ([@bib31]). However, the hexapeptide that mediates activation by Ca^2+^ in *C. elegans* is not present in mammalian or *Drosophila* DLK/Wnd, and mammalian DLK can be activated independently of Ca^2+^ elevation by cytoskeletal destabilizing agents ([@bib53]). In contrast, the consensus PKA phosphorylation site in the activation loop of Wnd/DLK is conserved in all phyla ([Figure 3C](#fig3){ref-type="fig"}), suggesting this pathway as a central (although not necessarily exclusive) mechanism for regulating DLK.

We note that in conjunction with phosphorylation of DLK's essential activation loop, PKA enhances DLK's stability via an additional mechanism ([Figure 4E](#fig4){ref-type="fig"}), since the mutated protein DLK^S302A^ can still be stabilized upon PKA activation. This mechanism may involve additional phosphorylation sites on DLK, and indeed, multiple PKA consensus sequences are observed in Wnd/DLK's sequence ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). However, it is also possible that PKA regulates DLK's stability via other mechanisms, such as previously described ubiquitination ([@bib35]; [@bib9]), palmitoylation modification ([@bib22]), changes in DLK's interacting proteins or subcellular localization. Such aspects of regulation could involve additional molecular targets of PKA, which would provide some potential for context specificity in DLK's regulation. While PKA has many cellular targets, its specificity can be highly regulated at a subcellular level by interactions with AKAP scaffolding proteins and local changes in cAMP ([@bib51]; [@bib59]). It will be interesting to identify the additional players in cAMP and PKA regulation of DLK through future work.

It is remarkable that PKA stimulates a specific increase in Wnd levels in axons but not cell bodies ([Figure 2C](#fig2){ref-type="fig"}), and inhibition of PKA strongly inhibits the induction of Wnd protein after axonal injury ([Figure 2D](#fig2){ref-type="fig"}). Does PKA act locally in axons to stimulate DLK? Other studies have suggested that Wnd/DLK can regulate retrograde signaling pathways that originate in axons ([@bib63]; [@bib18]; [@bib46]; [@bib24]; [@bib56]; [@bib67]; [@bib22]). Intriguingly, the Hiw/Rpm-1/Phr1 ubiquitin ligase, which is previously known for its role in regulating Wnd/DLK's levels in axons ([@bib9]; [@bib35]; [@bib26]; [@bib2]), contains a RCC1-like domain that biochemically inhibits adenylate cyclase, and therefore may negatively regulate cAMP signaling ([@bib40]). Hiw/Rpm-1/Phr1 is previously known for its role in regulating synaptic arborization and growth via its regulation of Wnd/DLK ([@bib35]; [@bib9]; [@bib55]; [@bib54]; [@bib47]). The addition of cAMP and PKA into this regulatory pathway suggests a mechanism that may be broadly utilized to orchestrate structural changes within presynaptic terminals. We propose that the regulation of DLK by PKA may be generally important for neuronal plasticity as well as responses to axonal damage.

Materials and methods {#s4}
=====================

Fly genetics {#s4-1}
------------

The following fly strains were used in this study: Canton-S (WT), m12-Gal4 ([@bib45]), BG380-Gal4 ([@bib4]), OK6-Gal4 ([@bib1]), RRa(eve)-Gal4 ([@bib16]), *puc*-lacZ^E69^, *wnd*^3^, UAS-Wnd, ([@bib9]), UAS-GFP-Wnd^KD^ ([@bib63]), UAS-PKA^CA^ ([@bib28]). UAS-Wnd^S301A,S305A^ flies were generated from pUAST-Wnd^S301A,S305A^ plasmid for this study. UAS-*wnd*-RNAi (VDRC 13786) and UAS-*moody*-RNAi (VDRC 100674) were from the Vienna RNAi center ([@bib10]). UAS-*pka-c1*-RNAis (31277, 35169) and UAS-*dnc*-RNAi (27250) were acquired from Bloomington stock center.

Nerve crush assay and immunocytochemistry in *Drosophila* {#s4-2}
---------------------------------------------------------

Peripheral nerve crush assays in 3^rd^ instar larvae were performed according to [@bib63]. Briefly, the segmental nerves of third instar larvae were pinched and crushed by a fine No.5 forceps while the larvae were anesthetized with CO~2~ gas. After injury, larvae were transferred to a grape plate and kept in 25°C incubator for specified time periods.

*Drosophila* third instar larva were dissected in ice-cold PBS and fixed in 4% paraformaldehyde for 25 min. Antibodies were used in PBS supplemented with 0.3% Triton and 5% normal goat serum. Anti-lacZ (40-1a, Developmental Studies Hybridoma Bank) was diluted 1:100. Anti-dsRed polyclonal antibody (632495, Clontech) was diluted 1:1000. For secondary antibodies, A488- or Cy3-conjucated goat anti-mouse or rabbit (Invitrogen, Carlsbad, CA) were used at 1:1000.

Imaging and quantification {#s4-3}
--------------------------

Confocal images were collected on an Improvision spinning disk confocal system, consisting of a Yokagawa Nipkow CSU10 scanner, and a Hamamatsu C1900-50 EMCCD camera, mounted on a Zeiss Axio Observer with 40X (1.3NA) oil objectives. Similar settings were used for imaging of all compared genotypes and conditions. Volocity software (Perkin Elmer) was used for intensity measurements and quantification of all confocal data.

A quantification of the sprouting response in injured motoneuron axons was measurement of the change of total volume of regenerating axonal membrane, labeled by mCD8-GFP, within a 100 µm distance from the injured tip. Pixels within the most distal 100 µm of the injured proximal stump were selected based on mCD8-GFP intensity criteria of \>3 standard deviation above the mean, and then summed to measure total membrane volume. [Figure 1](#fig1){ref-type="fig"} and [3F](#fig3){ref-type="fig"} report the change in average volume at 15 hr after injury compared to T=0 (immediately after injury).

*Puc*-lacZ expression was quantified by measurement of mean intensity for lacZ staining in the nuclei of motoneurons located along the dorsal midline (segments A3-A7) of the nerve cord of third instar larva. The mean intensity of GFP-Wnd^KD^ within segmental nerves was quantified by measuring GFP intensity within 100 µm distance of each nerve at the site of exit from the ventral nerve cord.

Cell culture {#s4-4}
------------

HEK293 cells were cultured in DMEM/F12 (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Gibco). For transient transfection, 1 µg of given vectors were transfected into 3.5 cm dish using Lipofectmine 2000 (Invitrogen). 20 hr after transfection, cells were processed for Western blotting. Plasmids used for transfection were Flag-DLK ([@bib24]), Flag-DLK^S302A^ ([@bib24]), Flag-DLK^K185A^ (directly generated from Flag-DLK) and PKA^CA^ ([@bib33]).

Primary neuron culture and mouse model {#s4-5}
--------------------------------------

Cortical neurons were dissected from E18 rat embryos. The cortex was digested by incubating with 0.5% trypsin-EDTA (Gibco) and DNAse I (Roche) at 37°C for 10 min. Following digestion, neurons were washed twice in DMEM medium (Gibco) containing 10% FBS before resuspension in neuronal growth media which containing neurobasal (Gibco), Glucose (Sigma), Glutamax (Gibco), penicillin-streptomycin and B27 supplement (Gibco). All the plates were coated with 100 µg/mL ploy-D-lysine (P7886, Sigma) for 2 hr. Neurons were then triturated and plated at a final concentration 400,000 cells/mL.

For adult DRG experiments, DRG neurons were collected from either CD1(Charles River), or Map3k12 F/F; Advillin-Cre-/- (WT), or Map3k12 F/F; Advillin-Cre+/- (DLK KO) mice. WT and DLK KO mice were age-sex matched. Neurons were prepared as previously described ([@bib15]). Briefly, DRG were digested for 15 min at 37°C with 0.35 mg/mL liberase Blendzyme (Roche), 10 mg/mL bovine serum albumin (Sigma), and 0.6 mg/mL DNase (Sigma) followed by another 15 min digest at 37°C with 0.05% trypsin. DRG were tritterated in culture media (DMEM containing 10% FBS, 100 µg/mL penicillin and 100 µg/mL streptomycin) to dissociated cells. Cells were plated on PDL (10 mg/mL) and laminin (10 mg/mL) coated plates. On day *in vitro* (DIV)1, half of the media was removed and fresh media containing AraC (Sigma, 10 nM final) was added. Drug treatment and replating were performed as described previously ([@bib15]). On DIV4, DMSO or forskolin (30 µM) were added to cells. 24 hr after drug application, drugs were washed out with DMEM. Neurons were lightly trypsinized with 0.025% trypsin for 5 min in the incubator (37°C, 5%CO~2~). Trypsin was removed and fresh culture media was added to the cells which were then gently pipetted and transferred to culture slides. 18 hr after replating, neurons were fixed (4% PFA) and stained for βIII-tubulin (Covance, mouse anti-Tuj1, 1:500). At least 100 neurons were imaged per group using either Leica DFC310 FX or DFC7000T color fluorescence cameras and longest neurite was traced using NeuronJ plugin for ImageJ. For replating experiments with PKA inhibitor (H-89, 5 µM), vehicle or inhibitor were added at the same time as DMSO and forskolin.

Immunochemistry, antibodies and chemicals {#s4-6}
-----------------------------------------

For detection of Wnd protein levels in larva nerve cords, the whole brains were carefully dissected from third instar larva. The two brain lobes were removed before they were frozen in liquid nitrogen and processed for western blotting (25 nerve cords per lane).

For western blots using HEK293 cells or cortical neurons, cells are lysed by incubating on ice for 10 min with RIPA buffer (BP-115, Boston BioProducts) supplemented with Complete protease inhibitor cocktail (Roche) and PhosSTOP phosphatase inhibitor (Roche). Protein concentrations were measured by BCA assay kit (Thermo Scientific).

Equal amount of protein samples were loaded on each lane of NuPAGE 4--12% Bis-Tris gels (Invitrogen) and subject to electrophoresis separation in MOPS buffer (Invitrogen). Blots were visualized with SuperSignal chemiluminescent substrate (Thermo Scientific) and exposure to either film or ChemiDoc (Bio-Rad). Bands intensities were determined using software ImageJ (NIH) using the gel analysis plug-in.

The following antibodies were used for Western blotting: anti-Wnd A3-1,2 at 1:700 ([@bib9]); anti-DLK at 1:5000 ([@bib24]); anti-β-tubulin at 1:1000 (E7; Developmental Studies Hybridoma Bank); anti-Flag at 1:1000 (F1804, Sigma); anti-PKA C (catalytic subunit) antibody at 1:1000 (4782, Cell signaling); anti-phospho-cJun antibody at 1:1000 (3270, Cell signaling); anti-phospho-S6K antibody at 1:1000 (9234, Cell signaling) and anti-S6K antibody at 1:1000 (2708, Cell signaling).

Anti-phospho-DLK^S302^ antibodies were raised by immunization of rabbits with the peptide KELSDKpSTKMpSFAGTV and affinity purified before use at dilution 1:100. While the antibodies were raised against a dually phosphorylated peptide (pS298, pS302), no difference in reactivity was noticed for DLK S298A mutants (data not shown).

Forskolin (F6886, Sigma) was applied to either HEK293 cells or cortical neurons at the final concentration of 30 µM for 6 hr. H-89 (B1427, Sigma) was used at the final concentration of 5 µM for cortical neurons for 6 hr. JNK inhibitor VIII (420135, EMD Millipore) was used at the final concentration of 10 µM on HEK293 cells for 6 hr. Torin1 (4247, Tocris) or Rapamycin (LC laboratories) was applied to the cells at 1 µM (final concentration) for 2 hr before harvest.

Protein phosphatase assay {#s4-7}
-------------------------

24 hr after transfection of the given constructs, HEK293 cells in a 6 cm dish were washed by ice-cold PBS and harvested in ice-cold RIPA buffer supplemented with EDTA-free protease inhibitor (Roche). The cell lysates were incubated on ice for 30 min and centrifuged at 14,000 rpm at 4°C for 10 min. The soluble lysate was incubated with 3 µg anti-Flag antibody pre-bound with 15 µl Dynabeads Protein G (Novex) for 1 hr at 4°C. After removal of supernatants the beads were washed 3 times with RIPA buffer, and then incubated with 1X PMP buffer (NEB), 1X MnCl~2~ (NEB) and either 1000 U lambda protein phosphatase (NEB) or equal amount of glycerol (control) in RIPA buffer for 30 min at 30°C. Beads were then removed from the reaction buffer and Flag-DLK was eluted by boiling in SDS sample buffer for 10 min. Equal amount of samples were analyzed by western blot.

*In vitro* PKA kinase assay {#s4-8}
---------------------------

HEK293 cells transfected with Flag-DLK were washed by ice-cold PBS and harvested using ice-cold cell lysis buffer (50 mM Tris-HCl, pH7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, Complete protease inhibitors (Roche) and 30 µM MG132 (Sigma)). Flag-tagged DLK was immunoprecipitated from HEK293 cell lysates using anti-Flag M2 antibody (Sigma) and Protein G Dynabeads (Novex). The DLK-bound beads were then washed with 3 times with lysis buffer and incubated with 2000 U lambda protein phosphatase (NEB) for 30 min at 30°C to remove all the phosphate groups. After incubation, the beads were washed with wash buffer containing cocktail phosphatase inhibitor (Roche) and split equally into two tubes containing kinase reaction buffer (50 mM Hepes, pH7.2, 10 mM MgCl~2~, 0.01% Triton X-100, 2 mM DTT, and 30 µM ATP). 10,000 U recombinant human full length PKA catalytic subunit alpha (NED Millipore) was added to one of the tubes, while the control tube were added with glycerol. Both tubes were incubated at 30°C for 90 min. Flag-DLK was eluted from beads by boiling in the SDS sample buffer. Equal amounts of samples were analyzed by western blotting with anti-DLK and anti-pDLK^S302^ antibodies.

Statistical analysis {#s4-9}
--------------------

For experiments in flies, we knew from previous work that a sample size of 10 animals per genotype was large enough to detect significant differences among genotypes ([@bib63]; [@bib62]). Therefore, at least 10 animals (≥ 50 axons) were examined and quantified in each genotype. Each experiment was repeated at least 3 times with independent biological replicates. For experiments in mice, we knew from previous work that measuring 100 neurons per genotype and an N=3--4 was sufficient to detect reproducible differences between the experimental groups ([@bib15]; [@bib53]). Therefore, all the experiments were performed with at least 3 independent biological replicates.

One way ANOVA and multiple comparisons were conducted when more than two samples are compared. Tukey post-hoc test was used to correct for multiple comparisons. For binned DRG neurites length distribution, statistical significance was determined by two way ANOVA followed by Bonferroni post-hoc test. p values smaller than 0.05 were considered statistically significant. All p values are indicated as \*p\<0.05, \*\*p\<0.01, and \*\*\*p\<0.001 and \*\*\*\*p\<0.0001. Data are presented as mean ± SEM.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"An evolutionarily conserved mechanism for cAMP elicited axonal regeneration involves direct activation of DLK\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Hugo Bellen as the Reviewing Editor and K VijayRaghavan as the Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Hao et al. describe an evolutionarily conserved mechanism mediating cAMP axonal regeneration via the phosphorylation of dual leucine zipper-bearing kinase (DLK). DLK (known as Wnd in *Drosophila*) has previously been implicated in invertebrate and mammalian systems to be essential for neuronal axon regeneration. DLK is enriched in axons after axonal injury, and DLK is required for injury-induced axonal regeneration in neurons of mammals, flies and worms. However, the specific mechanism by which DLK is activated is currently unknown, but multiple signaling pathways are likely to activate axonal regeneration. The authors focus on the cAMP-PKA signaling pathway, which stimulates axonal elaboration in multiple models systems of axon growth/regeneration. Based on an evolutionarily conserved PKA phosphorylation site residing in the kinase domain of DLK, the authors hypothesized that DLK phosphorylation lies downstream of the cAMP-PKA pathway to modulate DLK-dependent axonal regeneration. Consistent with this hypothesis, the authors demonstrate that DLK is subject to direct PKA phosphorylation at the proposed PKA phosphorylation site (S302). Additionally, the authors demonstrate in HEK293 mammalian cultured cells that DLK phosphorylation is enhanced (phospho-specific DLK antibody) when the PKA signaling pathway is activated either pharmacologically or by expression of constitutively activated PKA. The authors correlate DLK phosphorylation with enhanced DLK abundance in HEK293 cells and implicate a previously described JNK feedback pathway that affects DLK ubiquitination and degradation. These observations are consistent with their well-executed in vivo experiments demonstrating \#1) a genetic interaction in *Drosophila* between PKA and Wnd in mediating axonal regeneration after injury, \#2) enhanced levels of Wnd protein and activity after axonal injury or genetically activating the PKA pathway, and \#3) failure to rescue axonal regeneration by expressing the phosphorylation incapable Wnd S302A in the *wnd* mutant compared to WT controls.

PKA-phosphorylation of DLK/Wnd is a novel finding and of interest to the field of regeneration, unifying several previously described pathways into a coherent DLK-dependent pathway for injury-induced axon regeneration. Overall, the use of multiple model systems to describe DLK activation by PKA as a mechanism for axonal regeneration activation is one of the many strengths of this manuscript. Some comments for the authors to consider are noted below.

Essential revisions:

I recommend that the authors perform a few experiments to assess whether elevating cAMP levels in neurons mimics the expression of PKA^CA^ with regard to Wnd-dependent axonal sprouting and puckered induction. For instance, the authors could utilize loss-of-function alleles of the gene encoding the cAMP phosphodiesterase, *Dunce*. It will also be worthwhile to evaluate whether axon sprouting and puckered induction in dunce mutants are sensitive to Wnd knockdown. Conversely, the authors could examine if injury dependent axon sprouting and puckered induction are diminished if adenylyl cyclase (for e.g. Rutabaga or AC78C) levels are reduced.

Given that PKA activation leads to a strong upregulation of Wnd levels, I wonder whether Hiw and PKA function in the same pathway. I recommend that authors examine whether the increase in Wnd levels by PKA^CA^ is attenuated in the *hiw* mutants (by Westerns OR by imaging Wnd-GFP in axons). The results of this experiment will be interesting and relevant to this study regardless of the outcome! At the very least, the authors should discuss the stabilization of Wnd by PKA in the context of their previous findings regarding Hiw.

Is endogenous DLK/Wnd phosphorylated by PKA? The authors generated a beautiful DLK S302 phospho-specific antibody and successfully used it in transfected HEK293 cells expressing DLK. Can this antibody be used to demonstrate enhanced S302 phosphorylation of endogenous DLK/Wnd in *Drosophila* after expression of PKA^CA^ and/or axonal injury using westerns and/or immunostaining? Not sure if the antibody works across species, so this might not be an option. If not, has the antibody been tried in forskolin treated cultured cortical or DRG neurons? Would be a very nice positive addition to support the model, though not required given how difficult phospho-antibodies can be.

One point that could use some clarification for the readers is how the authors think that S302 phosphorylation actually affects DLK function. The authors nicely correlate DLK 302 phosphorylation with DLK abundance in transfected HEK293 cells. Huntwork-Rodriguez, in a prior study, reported that S302 of DLK is required for DLK protein stability (Huntwork-Rodriguez et al., 2013). That is, DLK downstream activation of the JNK pathway was proposed to result in a feedback loop in which JNK→DLK phosphorylation results in increased DLK abundance by reducing DLK degradation. There, the DLK^S302A^ mutant exhibited decreased overall DLK abundance by enhancing DLK degradation. Consistent with these previous findings, the current authors observed PKA-induced enhancement of DLK levels are blocked by JNK inhibitors without affecting S302 phosphorylation ([Figures 3E and 3F](#fig3){ref-type="fig"}). Interestingly, the DLK^K185A^ kinase dead version of DLK remains enhanced AND phosphorylated at S302 with PKA activation even in the presence of JNK inhibitors ([Figures 3G](#fig3){ref-type="fig"}), suggesting that elevation of DLK levels via S302 phosphorylation occurs *independent* of DLK kinase activity. How do the authors rationalize this in regards to their model ([Figure 3H](#fig3){ref-type="fig"}) and previous studies? For example, Huntwork-Rodriguez et al. found that the S302A mutation abolished the ability of DLK to activate downstream effectors (JNK). This observation led directly to a previous model that DLK kinase activates JNK to feedback and phosphorylate DLK and regulate its abundance. If both the DLK^K185A^ and DLK^S302A^ mutants lack kinase activity and fail to activate downstream effector pathways (e.g. JNK), why do they behave differently with JNK inhibitors? The authors\' statement that \"The induction of DLK activation loop phosphorylation independently of its own signaling abilities places PKA firmly upstream of DLK, as an upstream regulator/activator" (Results) seems true, but what does this data mean for the proposed model ([Figure 3H](#fig3){ref-type="fig"})? Finally, does DLK^S302A^ mutant fail to rescue in the *wnd* mutant rescue experiments ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), as they fail to increase in general abundance in response to injury and/or are the basal levels of DLK^S302A^ lower compared to WT DLK?

The authors placed the WT and WndS302A *Drosophila* rescue experiments in the supplemental figures, but I\'m not sure why these are not in the main text. As mentioned in \#2, failure of the DLK^S302A^ rescues to enrich DLK in axons after PKACA expression or axon injury would strengthen the authors model that PKA-dependent phosphorylation of DLK modulates its local stability to promote regeneration programs. Finally, are the DRG experiments amenable to rescue experiments with WT and DLK^S302A^ rescue experiments?

Axons vs. cell body. PKA activity has much more effect on *wnd* levels in axons than cell bodies. Does this mean PKA is activated by injury in axons but not cell bodies? This should be possible to test with a PKA activity reporter, and possibly also the phospho-specific *wnd* antibody.
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Author response

Essential revisions:

*I recommend that the authors perform a few experiments to assess whether elevating cAMP levels in neurons mimics the expression of PKA^CA^ with regard to Wnd-dependent axonal sprouting and puckered induction. For instance, the authors could utilize loss-of-function alleles of the gene encoding the cAMP phosphodiesterase, Dunce. It will also be worthwhile to evaluate whether axon sprouting and puckered induction in dunce mutants are sensitive to Wnd knockdown. Conversely, the authors could examine if injury dependent axon sprouting and puckered induction are diminished if adenylyl cyclase (for e.g. Rutabaga or AC78C) levels are reduced.*

In our revision we have included new data with knockdown of phosphodiesterase *Dunce* in *Drosophila* motoneurons, which leads to enhanced axonal sprouting response ([Figure 1](#fig1){ref-type="fig"}). These results are consistent with previously published data in *C. elegans* (Ghosh-Roy et al., 2010). Note that this previous study already showed that the enhanced regeneration in phosphodiesterase mutants required dlk-1 function.

We have also performed the puckered reporter analysis. We found that knockdown of Dunce in *Drosophila* motoneurons cause increased puckered expression in uninjured animals ([Figure 2A](#fig2){ref-type="fig"}), which is predicted from our model that cAMP activates DLK/Wnd signaling.

Given that PKA activation leads to a strong upregulation of Wnd levels, I wonder whether Hiw and PKA function in the same pathway. I recommend that authors examine whether the increase in Wnd levels by PKA^CA^ is attenuated in the hiw mutants (by Westerns OR by imaging Wnd-GFP in axons). The results of this experiment will be interesting and relevant to this study regardless of the outcome! At the very least, the authors should discuss the stabilization of Wnd by PKA in the context of their previous findings regarding Hiw.

We agree that the relationship between Hiw and PKA is very interesting to understand, particularly since some biochemical data in other species suggest that Hiw/Pam may regulate cAMP levels by inhibiting adenylate cyclase activity (Ehnert et al., 2004) (Pierre et al., 2004). Our data thus far suggest that the relationship is complex, so including data/experiments on this issue would be both distracting to the current story, and would require many more experiments to address the relationship properly. So instead we are following the reviewer's suggestion to discuss the regulation of Wnd by PKA in the context of what is previously known for Hiw, (in the Discussion section).

Is endogenous DLK/Wnd phosphorylated by PKA? The authors generated a beautiful DLK S302 phosphospecific antibody and successfully used it in transfected HEK 293 cells expressing DLK. Can this antibody be used to demonstrate enhanced S302 phosphorylation of endogenous DLK/Wnd in Drosophila after expression of PKACA and/or axonal injury using westerns and/or immunostaining? Not sure if the antibody works across species, so this might not be an option. If not, has the antibody been tried in forskolin treated cultured cortical or DRG neurons? Would be a very nice positive addition to support the model, though not required given how difficult phospho-antibodies can be.

We have tested the pS302-DLK antibody in flies and unfortunately it does not work across species. Over the past two months, we have tried hard to get a decent signal for endogenous DLK in cultured neurons, including scaled up cultures and immunoprecipitations to enrich for the protein. This has been very challenging technically -- we think that the levels of endogenous DLK are very low, and that the antibodies may also not be very sensitive. We prefer to leave this experiment out of the paper. As the phosphorylation of S302 is important for DLK to function as a kinase, our functional data combined with our biochemical data in HEK293 cells strongly suggests that S302 is indeed phosphorylated on endogenous DLK.

One point that could use some clarification for the readers is how the authors think that S302 phosphorylation actually affects DLK function. The authors nicely correlate DLK 302 phosphorylation with DLK abundance in transfected HEK293 cells. Huntwork-Rodriguez, in a prior study, reported that S302 of DLK is required for DLK protein stability (Huntwork-Rodriguez et al., 2013). That is, DLK downstream activation of the JNK pathway was proposed to result in a feedback loop in which JNK→DLK phosphorylation results in increased DLK abundance by reducing DLK degradation. There, the DLK^S302A^ mutant exhibited decreased overall DLK abundance by enhancing DLK degradation. Consistent with these previous findings, the current authors observed PKA-induced enhancement of DLK levels are blocked by JNK inhibitors without affecting S302 phosphorylation ([Figures 3E and F](#fig3){ref-type="fig"}). Interestingly, the DLK^K185A^ kinase dead version of DLK remains enhanced AND phosphorylated at S302 with PKA activation even in the presence of JNK inhibitors ([Figures 3G](#fig3){ref-type="fig"}), suggesting that elevation of DLK levels via S302 phosphorylation occurs independent of DLK kinase activity. How do the authors rationalize this in regards to their model ([Figure 3H](#fig3){ref-type="fig"}) and previous studies? For example, Huntwork-Rodriguez et al. found that the S302A mutation abolished the ability of DLK to activate downstream effectors (JNK). This observation led directly to a previous model that DLK kinase activates JNK to feedback and phosphorylate DLK and regulate its abundance. If both the DLK^K185A^ and DLK^S302A^ mutants lack kinase activity and fail to activate downstream effector pathways (e.g. JNK), why do they behave differently with JNK inhibitors? The authors\' statement that \"The induction of DLK activation loop phosphorylation independently of its own signaling abilities places PKA firmly upstream of DLK, as an upstream regulator/activator" (Results) seems true, but what does this data mean for the proposed model ([Figure 3H](#fig3){ref-type="fig"})?

We thank the reviewers for these points. We have carried out and included some additional experiments (which lead to an expansion of the previous [Figure 3](#fig3){ref-type="fig"} into two figures: [Figure 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). These data provide further clarification and lead to a revised model ([Figure 4E](#fig4){ref-type="fig"}). Both the S302A and K185A mutants appear to be 'kinase dead' since they are unable to stimulate downstream signaling, including phosphorylation of JNK and c-Jun (Huntwork-Rodriguez et al., 2013). We found that for both mutant proteins, PKA activation stimulates an increase in DLK levels ([Figure 4C, D](#fig4){ref-type="fig"}), even though they are incapable of downstream signaling. This suggests that PKA enhances DLK stability via an independent mechanism that is separate from the previously described JNK-dependent feedback mechanism. In further support of this, JNK inhibition acts additively with PKA activation ([Figure 4](#fig4){ref-type="fig"}). This revised model (in [Figure 4E](#fig4){ref-type="fig"}) unifies our observations with previous studies (including Huntwork-Rodriguez et al) and has some additional interesting implications for the regulation of DLK, which we have discussed further in this revised manuscript.

Finally, does DLK^S302A^ mutant fail to rescue in the wnd mutant rescue experiments ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), as they fail to increase in general abundance in response to injury and/or are the basal levels of DLK^S302A^ lower compared to WT DLK

Since independent transgenes have different expression levels, we cannot fairly assess the effect of the mutation upon basal expression levels. Using anti-Wnd antibodies to detect the over-expressed Wnd protein, we have examined basal and injury induced Wnd levels by immunocytochemistry. The transgenic protein is still quite hard to detect, and we do not observe an induction in Wnd^S301A,305A^ mutant protein after axonal injury. But we have caveats to reach any firm interpretations with this data, since we know that the expression levels of the mutant transgene is extremely high compared to endogenous Wnd.

The authors placed the WT and WndS302A Drosophila rescue experiments in the supplemental figures, but I\'m not sure why these are not in the main text. As mentioned in \#2, failure of the DLK^S302^A rescues to enrich DLK in axons after PKACA expression or axon injury would strengthen the authors model that PKA-dependent phosphorylation of DLK modulates its local stability to promote regeneration programs.

We appreciate this suggestion and have moved the rescue data into the main figures ([Figure 3G](#fig3){ref-type="fig"}). As discussed above and in our revised manuscript, the fact that this mutant protein is non-functional is important to emphasize since the stabilizing effect of PKA still occurs for the DLK^S302A^ mutant.

*Finally, are the DRG experiments amenable to rescue experiments with WT and DLK^S302A^ rescue experiments?*

We would like to do such rescue experiments. Unfortunately, they are not very feasible in adult DRG neurons. Both transfection and infection is very inefficient in adult DRG neurons for constructs the size of DLK. In addition, overexpression of DLK in neurons leads to DLK auto-activation and induces apoptosis.

Axons vs. cell body. PKA activity has much more effect on wnd levels in axons than cell bodies. Does this mean PKA is activated by injury in axons but not cell bodies? This should be possible to test with a PKA activity reporter, and possibly also the phospho-specific wnd antibody.

We agree that it is very interesting to know whether PKA regulates DLK locally in axons, however this is currently a very technically challenging question. The phospho-DLK antibodies do not work in flies, and our recent efforts lead us to conclude that they are also intractable for IHC in mammalian neurons (due to a high degree of non-specific staining). While a FRET reporter has been used for PKA in flies (Gervasi et al., 2010), it has never been used before in our larval motoneuron preparation. We have begun to work with a cAMP FRET reporter that is more widely used in *Drosophila* (Ponsioen et al., 2004) and still have a great deal of troubleshooting to carry out in order to implement the reporter in a new preparation and verify that it is working properly. The PKA reporter would require even further validation and controls. We think this is an interesting future project, but is not practical for this current story. An important additional caution is that even if any of these suggested assays work, a negative result in our injury assays could still have the caveat that the method of detection is not sensitive enough to detect functional changes that indeed occur.
